Stay updated on Intratumoral IMO-2125 in Refractory Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Intratumoral IMO-2125 in Refractory Solid Tumors Clinical Trial page.

Latest updates to the Intratumoral IMO-2125 in Refractory Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now presents the ClinicalTrials.gov record for the completed Phase 1b ILLUMINATE-101 study of intratumoral IMO-2125, including eligibility criteria, study locations, treatment details, and outcome measures.SummaryDifference45%

- Check21 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the page content remains a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide banner announces NIH website transition updates and says some NIH content may use “Super Intelligence” instead of “Artificial Intelligence”.SummaryDifference1%

- Check35 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check42 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record view for this NCT entry. This indicates the content is not accessible at this URL.SummaryDifference17%

Stay in the know with updates to Intratumoral IMO-2125 in Refractory Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Intratumoral IMO-2125 in Refractory Solid Tumors Clinical Trial page.